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Prions are the unconventional infectious agents responsible for prion diseases, which are composed
mainly by the misfolded prion protein (PrPSc) that replicates by converting the host associated cel-
lular prion protein (PrPC). Several lines of evidence suggest that other cellular components partici-
pate in prion conversion, however, the identity or even the chemical nature of such factors are
entirely unknown. In this article we study the conversion factor activity by complementation of a
PMCA procedure employing puriﬁed PrPC and PrPSc. Our results show that the conversion factor
is present in all major organs of diverse mammalian species, and is predominantly located in the
lipid raft fraction of the cytoplasmic membrane. On the other hand, it is not present in the lower
organisms tested (yeast, bacteria and ﬂies). Surprisingly, treatments that eliminate the major classes
of chemical molecules do not affect conversion activity, suggesting that various different com-
pounds may act as conversion factor in vitro. This conclusion is further supported by experiments
showing that addition of various classes of molecules have a small, but detectable effect on enhanc-
ing prion replication in vitro. More research is needed to elucidate the identity of these factors, their
detailed mechanism of action and whether or not they are essential component of the infectious
particle.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Compelling evidence indicate that prions are composed exclu-
sively of the misfolded prion protein (termed PrPSc), which trans-
mit the disease in the absence of nucleic acids by transferring its
folding properties to the normal cellular prion protein (PrPC) pres-
ent in the host. The prion hypothesis remained highly controversial
for decades until recent studies in which infectious PrPSc was suc-
cessfully generated in a cell-free system [1–6]. Prion replication is
hypothesized to occur when PrPSc in the infecting inoculum inter-
acts speciﬁcally with host PrPC, catalyzing its conversion to the
misfolded form of the protein. A physical association between
the two isoforms during the infectious process is suggested by
the primary sequence speciﬁcity in prion transmission [7] and by
the reported in vitro generation of PrPSc by mixing puriﬁed PrPC
with PrPSc [8,9]. However, the exact mechanism underlying the
conversion is not known, particularly with respect to the putative
role of other cellular factors in prion replication [10].
The existence of a host factor involved in prion replication was
ﬁrst suspected when transgenic mice expressing both human andchemical Societies. Published by E
Houston, TX 77546, USA.
).
logy and Toxicology, Centre
ne, Switzerland.mouse PrPC were challenged with human prions. Surprisingly,
mice co-expressing both proteins were resistant to prion replica-
tion while mice expressing only human PrPC developed the disease
following inoculation with human prions [7]. Interestingly, trans-
genic animals expressing a chimeric protein consisting of pieces
of the human and the mouse gene were also susceptible to infec-
tion with human prions [11]. The interpretation of these results
was that mouse PrPC inhibited the conversion of human PrPC by
binding to an additional cellular protein implicated in prion repli-
cation. Further studies performed by the same group showed that
the host factor, termed ‘‘protein X”, was able to bind PrPC through
its C-terminal end [12] and this interaction can be precluded by
some small molecule compounds [13]. More recent biochemical
studies have provided additional evidence for the existence of a
conversion factor in prion replication. We demonstrated previously
that in vitro prion conversion does not occur under our experimen-
tal conditions when puriﬁed PrPC and PrPSc are mixed and incu-
bated [14]. The conversion activity was recovered when the bulk
of cellular components were added back to the sample [14]. In a
series of elegant studies, Supattapone and colleagues have shown
that small, highly structured RNA, vertebrate RNA and, homopoly-
meric nucleic acids such as poly(A) and poly(dT) can take the place
of the cellular conversion factor to enable PrPC to PrPSc conversion
by PMCA (Protein Misfolding Cyclic Ampliﬁcation) and generation
of infectious material [2,15–17]. Their ﬁndings revealed that RNAlsevier B.V. All rights reserved.
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complexes with PrP during prion formation. Very recently, Wang
et al., reported the de novo generation of PrPSc and infectivity when
puriﬁed recombinant PrP was subjected to PMCA in the presence of
RNA and lipids [4].
The aim of this work was to study the nature of the conversion
factors implicated in prion replication by evaluating the ability of
different cellular fractions to complement in vitro conversion of
puriﬁed PrPC and PrPSc in PMCA assays.2. Materials and methods
2.1. PrPC puriﬁcation
PrPC was puriﬁed from brain extracts using magnetic beads
covered by 3F4 antibody (Covance). Magnetic beads-3F4 complex
was prepared by incubating anti-mouse IgG covered Dynabeads
M-280 (Invitrogen) with the antibody for 2 h at 4 C. Glutaralde-
hyde was used in the process in order to avoid 3F4 release in
the PrPC elution process. Then immunoprecipitation was per-
formed by using Syrian hamster (SHa) brain homogenates cleared
by a short centrifugation process (2000g for 2 min using an
eppendorf 5810 R centrifuge). Samples were incubated overnight
at 4 C with shaking and then three sequential elutions of PrPC in
Conversion Buffer (1% Triton X-100 in PBS without Ca2+ and
Mg2+) containing 2.5 M NaCl. Collected PrPC was pooled and con-
centrated using YM-10 microcon ﬁlters (Millipore) at 16 000g
and 4 C until complete ﬁltration of the sample. A PBS wash was
later performed in order to remove salt excess. Finally, concen-
trated samples were collected by inverting the ﬁlter device in a
new eppendorf tube and centrifuging for 2 min at 5000g. The
recovery yield was checked by Western blotting using 3F4 anti-
body. The purity of the preparation was checked by sodium dode-
cylsulphate polyacrylamide gel electrophoresis (SDS–PAGE)
followed by silver staining and Western blots.2.2. PrPSc puriﬁcation
Brains from symptomatic Chinese hamsters (Cha) infected with
the 263 K prion strain were homogenized at 10% in PBS. Samples
were sonicated and centrifuged at 5000 rpm for 30 s using an
eppendorf 5810 R centrifuge. Supernatants were mixed with 1/3
volume of PBS-Zwittergent 3-14 (Calbiochem), 10% sarkosyl and
centrifuged for 2 h at 100 000g in a Biosafe Optima MAX ultra-
centrifuge (Beckman–Coulter). Pellets were resuspended in PBS
containing 10% NaCl and 0.1% Zwittergent 3–14 and sonicated.
The resulting material was placed in a sucrose cushion (20% su-
crose prepared in PBS plus 10% NaCl and 0.1% Zwittergent 3–14)
and centrifuged at 100 000g for 3 h. Pellets were resuspended
in PBS containing 0.1% SB3–14 and the preparation was treated
with proteinase K (PK) (100 lg/mL) for 2 h at 37 C. PK treated
samples were placed over a sucrose cushion and centrifuged at
100 000g for 1.5 h. Finally, pellets were resuspended in PBS and
purity was analyzed by silver staining. All centrifugation processes
were performed at 4 C.2.3. Preparation of tissue homogenates
Tissues from different organs (liver, kidney, brain, heart and
muscle from rabbit) were homogenized at 10% in CB (1% Triton
X-100 and 150 mM NaCl in PBS plus Complete Protease Inhibitors
Cocktail (Roche)). The same procedure was applied for lower
organism tested. Homogenates were cleared by centrifuging the
samples at 2000 rpm for 45 s at 4 C.2.4. Protein Misfolding Cyclic Ampliﬁcation (PMCA)
The PMCA procedure has been extensively explained elsewhere
[18–20]. Brieﬂy, puriﬁed Sha-PrPC complemented with several tis-
sue homogenates or chemicals (Poly-A, bovine serum albumin,
heparin or a mixture of fatty acids) were mixed with puriﬁed
Cha-PrPSc and submitted to 96 cycles of PMCA. A cocktail of prote-
ase inhibitor was added to the sample (except when the effect of
the proteases was evaluated) to avoid degradation of the substrate.
Samples were loaded onto 0.2-mL PCR tubes. Tubes were posi-
tioned on an adaptor placed on the plate holder of a microsonicator
(Misonix Model 3000, Farmingdale, NY) and programmed to per-
form cycles of 30 min incubation at 37 C followed by a 20 s pulse
of sonication set at potency of 7.5 (75%). Samples were treated
with 50 lg/mL of PK for 1 h at 37 C and ampliﬁcation of misfolded
prions was assessed by Western blotting as explained below.
2.5. Western blotting
PK treated samples were fractionated by SDS–PAGE and trans-
ferred to Hybond Nitrocelulose membranes (Amersham) and
probed using 3F4 or 6H4 antibodies (Prionics). Reaction was devel-
oped using ECL Plus system (Amersham).
2.6. Isolation of lipid raft fractions
Brain homogenates from rabbit were homogenized in CB and
mixed with iodixanol (ﬁnal concentration, 40%). The resulting mix-
ture was deposited in the bottom of an ultracentrifugation tube
and two layers of 35% and 30% iodixanol were added in order to
generate a discontinuous gradient. Ultracentrifugation was per-
formed at 200 000g for 4 h. The fraction containing lipid rafts mi-
grates at the interface between the top layer and the adjacent
denser layer and can be easily collected with a pipette. In order
to wash the samples from Triton X-100 and iodixanol, samples
were mixed with nine volumes of cold PBS and further ultracentri-
fuged at 200 000g for 2 h. Supernatant was carefully discarded
and pellet containing the lipid raft was resuspended in CB. All pro-
cedures were performed at 4 C. The presence of lipid rafts was
analyzed for their PrPC and Fyn content by Western blot with spe-
ciﬁc antibody: 6H4 for PrPC (Prionics) and anti-Fyn (Santa Cruz).
2.7. Enzymatic treatment of brain homogenates
Brain homogenates were treated with benzonase (1.65 units/
mL, 45 min at 37 C), Heparinase II and Heparinase III (0.5 units/
mL, 1 h at 37 C), Chondroitinase ABC (0.5 units/mL, 1 h at 37 C),
and lipase A (5% v/v, 1 h at 37 C). In the case of protein degrada-
tion by trypsin and PK, samples were incubated with the enzyme
at a ﬁnal concentration of 0.5 mg/mL (1.5 h at 37 C). Before adding
to the PMCA mixture, protease activity was stopped by heating the
samples for 15 min at 85 C. The resulting sample in each case was
used to measure conversion activity in vitro. The efﬁciency of the
procedures to eliminate nucleic acids and proteins was checked
by electrophoresis.
3. Results
In order to develop a clean biochemical assay to evaluate for
conversion factor activity, we worked with PrP proteins from Syr-
ian and Chinese hamsters, two close hamster species in which
there is only a small species barrier [21]. Despite the high sequence
conservation between these species, only Syrian hamster (Sha) PrP
is recognized with the widely used 3F4 antibody. In vitro conver-
sion experiments showed that Sha-PrPC was efﬁciently converted
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slightly lower than the one obtained when Cha-PrPSc was propa-
gated at expenses of Cha-PrPC. The advantage of working with
the heterologous mixture is that any signal observed with the
3F4 antibody corresponds to newly generated Sha-PrPSc and not
to the inoculum added to trigger conversion.
To develop the conversion factor complementation assay, we
partially puriﬁed Sha-PrPC by afﬁnity chromatography, as de-
scribed in Methods. Analysis by silver staining and Western blot
after polyacrilamide gel electrophoresis revealed that PrPC is more
than 70% pure (Fig. 1B). Incubation of this puriﬁed Sha-PrPC with
highly puriﬁed Cha-PrPSc (using a standard procedure that results
in > 90% purity) produced no ampliﬁcation by PMCA (Fig. 1C).
Strikingly, a large amount of conversion product was observed
when the same mixture was supplemented with 10% Cha normal
brain homogenate (Fig. 1C). This result conﬁrms our previousFig. 1. PMCA complementation assay to study conversion factor activity. (A) Golden
Syrian hamster normal brain homogenate (NBH) containing PrPC was incubated
with various dilutions of Sha or Cha scrapie sick brain homogenate. Samples were
subjected to 96 PMCA cycles and either frozen (mixture without PMCA) or PMCA
ampliﬁed material were analyzed by Western blot (after PK digestion) with the 3F4
antibody that detects Sha PrP, but not Cha PrP. (B) PrPC was partially puriﬁed from
Sha normal brain homogenate by afﬁnity chromatography as described in methods.
Both unpuriﬁed (U) and puriﬁed (P) samples were analyzed by silver staining (left
panel) or Western blotting (right panel) using the 3F4 antibody. (C) Mixtures of
puriﬁed Sha-PrPC and Cha-PrPSc were subjected to PMCA ampliﬁcation in the
presence of conversion buffer or 10% Cha normal brain homogenate (NBH). PrPSc
signal was evaluated after PK treatment by Western blot using 3F4 antibody.publication [14] and provides an excellent biochemical assay to
test for conversion factor activity.
We ﬁrst studied the species-speciﬁcity of the conversion factor
by complementing the PMCA assay using puriﬁed Sha-PrPC and
Cha-PrPSc with brain homogenates from other mammal species.
Brain homogenates from mice, prnp knock out mice and rabbits
were able to complement prion conversion with similar efﬁciency
as Cha tissue (Fig. 2A). This result indicates that the conversion fac-
tor is not species-speciﬁc and is likely present in the brain of var-
ious mammal species, including rabbit, an animal which is highly
resistant to prion infection [22]. However, addition of similar quan-
tities of total extracts from lower organisms, including bacteria,
yeast and drosophila was unable to complement prion conversion
(Fig. 2B), although a faint band with the yeast extract was detected
in some experiments. These results indicate that the conversion
factor was not present in these evolutionary lower organisms.
Next, we studied whether the conversion factor was present in
other major organs and tissues. PMCA complementation using
10% homogenates from liver, kidney, heart and muscles from rab-
bit produced a similar level of prion replication as the brain tissueig. 2. Conversion factor activity in various tissue homogenates and extracts from
istinct species. (A) To study species-speciﬁcity of conversion factor, PMCA of
uriﬁed Sha-PrPC and Cha-PrPSc was complemented with 10% brain homogenates
om Cha, rabbit and PrP knockout mice. Buffer corresponds to the negative control
which no tissue homogenate (only buffer) was added to the sample. Mixtures
ere subjected to 96 PMCA cycles and formation of Sha-PrPSc was checked by
estern blot after PK digestion. (B) A similar experiment as described in (A) was
one using as complement 10% (w/v) extracts of bacteria (Escherichia coli), yeast
accharomyces cerevisiae) or ﬂy (Drosophila melanogaster). Again the efﬁciency of
MCA complementation was checked by Western blot using 3F4 antibody. (C) The
resence of conversion factor activity in various major organs (liver, kidney, brain,
eart and muscles) was evaluated by using 10% tissue homogenates to complement
MCA using puriﬁed proteins. In the blots showed in this ﬁgure all samples were
eated with PK to remove non-converted PrPC, except in the migration control
BH, No PK), which correspond to full-length Sha-PrPC.F
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sive of the brain, but is present in other major mammalian organs.
PrP is a cell surface protein located in specialized membrane
micro-domains known as lipid rafts [23,24]. Since it is likely that
prion conversion takes place with PrPC bound to the membrane
either on the cell surface or in endocytic vesicles [25], we reasoned
that the conversion factor should be located in lipid rafts. To eval-
uate this hypothesis we puriﬁed lipid rafts from rabbit brain
homogenate employing density gradient centrifugation, as de-
scribed in Section 2. The efﬁciency of the lipid raft preparation
methodology was checked using the lipid raft markers Fyn and
PrPC (Fig. 3A). Then each fraction of the gradient was tested for
its ability to complement PMCA conversion of puriﬁed Sha-PrPC
triggered by puriﬁed Cha-PrPSc. As seen in Fig. 3B, the two fractions
corresponding to the lipid raft preparation (fractions 1 and 2)
showed the highest ability to complement prion conversion. This
result is not dependent on the presence of PrPC in the complement-
ing material, since similar results were obtained when lipid rafts
were puriﬁed from prnp/ mice brain (data not shown). Some
other fractions of the gradient showed a much lower, but detect-
able, conversion factor activity (e.g. fractions 3, 4, 6, 9 and 10). Con-
sidering that lipid rafts correspond to a very small fraction of the
total brain, our ﬁndings suggest that lipid rafts might be an excel-
lent starting point to attempt isolating the conversion factor by
biochemical fractionation of this preparation.
To investigate in more detail the chemical nature of the conver-
sion factor we subjected the brain homogenate samples to treat-
ments that destroy different classes of molecules, including
nucleic acids (benzonase, a promiscuous endonuclease that cleaves
all forms of DNA and RNA), proteins (proteinase K and trypsin), lip-
ids (lipase A) and proteoglycans (heparinase II and III and chondro-
itinase ABC). PMCA complementation assays using rabbit brain
homogenates previously treated to destroy these different mole-
cules did not produce any effect on conversion factor activity
(Fig. 4A). These surprising results suggest that different classes ofFig. 3. The conversion factor is located on membrane lipid rafts. (A) Lipid rafts were puriﬁ
methods. Different fractions from the gradient were loaded into SDS–PAGE and analyz
expected the lipid raft markers appears on fractions 1 and 2 of the gradient (highlighted b
of puriﬁed Sha-PrPC and Cha-PrPSc. Samples were subjected to 96 PMCA cycles and for
control samples were complemented with Rabbit normal brain homogenate (NBH) andmolecules can act as conversion factors and when one is removed
the other one plays the role in vitro. Alternatively, it could be spec-
ulated that the conversion factor was not degraded by the treat-
ments employed or belong to a class of molecules that was not
affected by the enzymes used. No effect on prion replication was
also observed when the brain homogenate was heated at either
85 C or 100 C. Indeed only a small decrease on PMCA efﬁciency
was observed when the puriﬁed Cha-PrPSc and Sha-PrPC were com-
plemented with rabbit brain homogenate pre-heated at 100 C
during 30 min (Fig. 4B). These results further support the idea that
the conversion factor is not a protein or any structure that can be
heat-denatured. Finally to rule out that the conversion factor could
be small ions (e.g. metals), amino acids, nucleotides or degradation
products from macromolecules (e.g. small peptides), the brain
homogenate was ﬁltered using 10 kDa cut off ﬁlters. The ﬁltrated
material was unable to complement prion conversion (Fig. 4C),
suggesting that the conversion factor is not a small chemical com-
pound, such as salts, ions or other chemical molecules.
It has been suggested that the conversion factor might be a pro-
tein, RNA (or other polyanionic molecules), lipids or proteoglycans
[4,15,16,26,27]. To assess the potential of this type of molecules to
complement prion conversion in vitro, we carried out our assay in
the presence of high concentrations of poly-A synthetic RNA, bo-
vine serum albumin, heparin and a mixture of various fatty acids
(Fig. 5). The results of these studies showed that although these
molecules induce a small increase of PMCA ampliﬁcation com-
pared to the control experiment done in the absence of these mol-
ecules, the conversion efﬁciency is far lower than when
complemented with entire brain homogenate. The interpretation
of these results is that various classes of molecules may help in a
rather unspeciﬁc way PrPC to PrPSc conversion in vitro. It is possible
that in vivo a mixture of various molecules may play the conver-
sion factor role, although our negative results with extracts from
lower organisms suggest that speciﬁc mammalian factors are
necessary for high conversion efﬁciency.ed from rabbit brain homogenate by density gradient centrifugation as described in
ed by Western blot using the anti-PrP antibody 3F4 and the anti-Fyn antibody. As
y a box). (B) Equal volume from each of the fractions was used to complement PMCA
mation of new PrPSc was checked by Western blot using 3F4 antibody. As positive
as negative control, only buffer was added to the mixture of puriﬁed proteins.
Fig. 4. Depletion of various classes of chemical molecules does not decrease conversion factor activity. (A) Rabbit brain homogenate was subjected to treatments to remove
diverse classes of molecules, including lipids (lipase A), nucleic acids (benzonase), proteins (Trypsin and PK) and proteoglycans (Heparinase II and III and chondroitinase ABC).
The efﬁciency of the removal of these molecules was checked by gel electrophoresis. In the case of the proteases, before addition of the treated mixture, the samples were
heated at 85 C to inactivate the proteases. The materials were used to complement PMCA reaction using puriﬁed Sha-PrPC and Cha-PrPSc. Positive controls corresponded to
complementation with non-treated samples of 10% rabbit brain homogenate (labeled as ‘‘no treat” in the ﬁgure). Negative controls corresponded to samples in which buffer
was added to the mixture. All samples were treated with PK before Western blotting, except the migration control (NBH). (B) Samples of 10% rabbit brain homogenate were
heated at either 85 C or 100 C for the indicated times. After cooling, samples were used to complement PMCA reaction of puriﬁed proteins. (C) Samples of 10% rabbit brain
homogenate were ﬁltered using a 10 kDa cut off ﬁlter. Filtrated material was used to complement PMCA of puriﬁed proteins. Samples were subjected to 96 PMCA cycles and
formation of new PrPSc was checked by Western blot using 3F4 antibody. As positive control samples were complemented with Rabbit normal brain homogenate (NBH).
Fig. 5. Diverse classes of molecules can enhance prion conversion in vitro. The PMCA reaction of puriﬁed Sha-PrPC and Cha-PrPSc was complemented by adding the indicated
concentrations of synthetic poly-A RNA, bovine serum albumin (BSA), heparin or a mixture of fatty acids (Sigma) prepared in water (including methyl octanoate, nonanoate,
decanoate, undecanoate, laurate, tridecanoate, myristate, pendecanoate, palmitate and heptadecanoate). Samples were subjected to 96 PMCA cycles and generation of Sha-
PrPSc was evaluated by Western blots using 3F4 antibody. As before, the positive control corresponded to samples complemented with rabbit normal brain homogenate
(NBH) and as negative control, only buffer was added to the mixture of puriﬁed proteins. All samples were treated with PK to remove non-converted PrPC, except in the
migration control (NBH, No PK), which correspond to full-length Sha-PrPC.
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Transmission of TSEs is dependent on the auto-catalytic forma-
tion of PrPSc at expenses of the host PrPC. In spite of substantial
research on the nature of the prion infectious agent, the molecular
and structural bases of prion replication are still largely unknown.
One of the most important issues concerning the mechanism of
prion replication is to determine the identity of the cellular co-
factors involved in the process. Despite that the involvement of
cellular co-factors in prion conversion is suspected since more than
15 years ago, the identity or even the chemical nature of these
factors is completely unclear [10]. It is also unknown whether
the co-factor is one speciﬁc molecule or several rather non-speciﬁc
molecules that accidently participate in prion conversion.
The results described in this article provide further evidence
for the existence of cellular factors involved in prion conversion.
These conversion factors appear to be present in all major organs
of mammals, but do not exist in lower organisms, including yeast,bacteria or ﬂy. The conversion factor activity is enriched in the
lipid raft fraction of cellular membranes and do not appear to
be responsible for species barrier. Surprisingly, treatments that
destroy all major type of chemical molecules do not affect con-
version activity, neither does heating at high temperatures. One
interpretation of these results is that various types of molecules
can act as conversion factors in vitro, catalyzing PrPC to PrPSc for-
mation in the presence of PrPSc template. Indeed, our results indi-
cate that synthetic poly-A RNA, fatty acids, proteins (BSA) and
heparin can partially replace the conversion factor activity in
our in vitro assay, conﬁrming previously published results
[4,15,16,26,27]. However, these molecules have far lower efﬁ-
ciency than the endogenous conversion factors present in mam-
malian tissues. Overall our ﬁndings indicate that although prion
conversion can be slightly enhanced with various classes of
chemical molecules, high efﬁciency prion replication requires fac-
tors that are speciﬁcally located in the lipid rafts of mammalian
cells.
2414 K. Abid et al. / FEBS Letters 584 (2010) 2409–2414Elucidating the nature of the prion conversion factors would not
only be important to understand the mechanism of prion
replication, but would also provide novel targets for therapeutic
intervention. Indeed, if the interaction of PrP with these additional
co-factors is essential for PrPSc formation, compounds disrupting
this interaction would likely prevent prion disease.
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